At Creative Animodel, we offer a wide range of CDX or PDX models for efficacy studies, either as subcutaneous models or as orthotopic and metastasis models in immunodeficient mice. Our tumor-bearing, humanized-xenograft models also has the potential to meet your requirement of preclinical evaluation of immunotherapies. Besides, our efficacy testing platform provides customers with study designs which are individually tailored to your needs within a reasonable timeframe, indicating a proof of concept or therapeutic efficacy validation. Services in Creative Animodel include the following categories, but are not limited to:
• Efficacy tests on subcutaneous models
• Efficacy tests on orthotopic, metastatic and disseminated tumor models
• Assessment of therapeutic antibodies
Monoclonal antibodies are promising therapies at present, especially for hematological malignances such as the application of Rituximab in the treatment of NHL. Creative Animodel has established unique models and experimental techniques which enabling the translation of your developed monoclonal antibody into preclinical tests. The detection of pharmacokinetics (ELISA), bioavailability (biodistribution of radiolabeled Abs by whole-body autoradiography, organ radioactivity analysis or PET imaging), as well as the albumin-conjugate in vivo of the mAb can be achieved through our humanized-xenografts. In addition, Creative Animodel also supports combinational therapy tests to evaluate curative effect by changing administration sequences and dosages.
Customers` benefits include the following aspects, but are not limited to:
1.Koyama D1, Kikuchi J1, Hiraoka N1, et.al.Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia. 2014 Jun;28(6):1216-26.
2.Marubayashi S, Koppikar P, Taldone T, et.al.HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice ans humans, J Clin Invest. 2010 Oct;120(10):3578-93.
3.Sanda T1, Li X, Gutierrez A, Ahn Y, et.al.Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. Blood. 2010 Mar 4;115(9):1735-45.